We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+48.34%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$161M
AUM Growth
+$37.1M
Cap. Flow
-$4.8M
Cap. Flow %
-2.99%
Top 10 Hldgs %
82.84%
Holding
41
New
2
Increased
4
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$2.91M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$1.13M
3
PACB icon
Pacific Biosciences
PACB
+$1.13M
4
KALV
KalVista Pharmaceuticals
KALV
+$634K
5
GERN icon
Geron
GERN
+$311K

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$9.99M
2
OCS icon
Oculis Holding
OCS
+$911K
3
AKRO
Akero Therapeutics
AKRO
+$224K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$71.4M 44.49%
225,688
– –
ILMN icon
2
Illumina
ILMN
$30.8B
$16.6M 10.34%
122,533
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.02B
$11.9M 7.42%
368,665
– –
OCS icon
4
Oculis Holding
OCS
$683M
$5.83M 3.63%
518,933
-87,751
-14% -$911K
EXAI
5
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$5.51M 3.43%
859,892
– –
ALPN
6
DELISTED
Alpine Immune Sciences Inc
ALPN
$5.03M 3.13%
263,940
+81,660
+45% +$1.13M
XENE icon
7
Xenon Pharmaceuticals
XENE
$6.11B
$4.91M 3.06%
106,680
– –
SLGC
8
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$4.29M 2.67%
1,696,558
– –
MRUS
9
DELISTED
Merus
MRUS
$3.77M 2.35%
137,038
– –
KALV
10
DELISTED
KalVista Pharmaceuticals
KALV
$3.73M 2.32%
304,277
+69,704
+30% +$634K
MIRM icon
11
Mirum Pharmaceuticals
MIRM
$6.59B
$2.84M 1.77%
+96,100
New +$2.91M
PACB icon
12
Pacific Biosciences
PACB
$444M
$2.69M 1.68%
274,488
+137,833
+101% +$1.13M
ONC
13
BeOne Medicines Ltd
ONC
$32.7B
$2.17M 1.35%
12,022
– –
INCY icon
14
Incyte
INCY
$24.3B
$2.01M 1.25%
32,022
– –
GERN icon
15
Geron
GERN
$795M
$1.93M 1.2%
913,550
+160,000
+21% +$311K
RYTM icon
16
Rhythm Pharmaceuticals
RYTM
$6.78B
$1.84M 1.15%
40,070
– –
RANI icon
17
Rani Therapeutics
RANI
$89.2M
$1.64M 1.02%
493,584
– –
REPL icon
18
Replimune Group
REPL
$895M
$1.56M 0.97%
184,739
– –
EXEL icon
19
Exelixis
EXEL
$13.4B
$1.54M 0.96%
64,200
– –
BOLT icon
20
Bolt Biotherapeutics
BOLT
$7.65M
$1.31M 0.81%
58,348
– –
JBIO
21
Jade Biosciences
JBIO
$1.21B
$1.08M 0.68%
1,370
– –
CABA icon
22
Cabaletta Bio
CABA
$432M
$1.07M 0.67%
47,150
– –
ACAD icon
23
Acadia Pharmaceuticals
ACAD
$4.4B
$939K 0.58%
29,984
– –
TRDA icon
24
Entrada Therapeutics
TRDA
$265M
$741K 0.46%
49,082
– –
ALXO icon
25
ALX Oncology
ALXO
$265M
$625K 0.39%
41,950
– –
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q4 2023 Portfolio in Review

As of Q4 2023, Nan Fung Group Holdings held 41 positions worth $161M, up 30% from $123M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Nan Fung Group Holdings's Q4 2023 filing shows 2 new, 4 increased, 1 reduced and 2 closed positions. Its largest new stake was Mirum Pharmaceuticals: 96,100 shares worth $2.84M. The largest sale was Seagen Inc. Common Stock, an estimated $9.99M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Nan Fung Group Holdings's largest Q4 2023 buy was Mirum Pharmaceuticals: 96,100 shares worth $2.84M.
  • Nan Fung Group Holdings added most to Alpine Immune Sciences Inc in Q4 2023, an estimated $1.13M increase.
  • Nan Fung Group Holdings's biggest Q4 2023 reduction was Oculis Holding, cutting an estimated $911K.
  • Nan Fung Group Holdings fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $9.99M.
  • Nan Fung Group Holdings's ten largest holdings make up 83% of its $161M portfolio in Q4 2023.
  • Nan Fung Group Holdings opened 2 new positions and closed 2 in Q4 2023.
  • Nan Fung Group Holdings's portfolio value rose 30% quarter-over-quarter to $161M.

Based on Nan Fung Group Holdings's 13F filing for Q4 2023, filed 13 Feb 2024.